BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 29618661)

  • 21. Survival results in biphasic malignant pleural mesothelioma patients: A multicentric analysis.
    Lococo F; Torricelli F; Lang-Lazdunski L; Veronesi G; Rena O; Paci M; Casadio C; Piana S; Novellis P; Di Stefano TS; Ciarrocchi A; Billè A
    J Thorac Cardiovasc Surg; 2020 Apr; 159(4):1584-1593.e2. PubMed ID: 31590954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma.
    Al-Taei S; Salimu J; Lester JF; Linnane S; Goonewardena M; Harrop R; Mason MD; Tabi Z
    Lung Cancer; 2012 Aug; 77(2):312-8. PubMed ID: 22498111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.
    Cheng YY; Kirschner MB; Cheng NC; Gattani S; Klebe S; Edelman JJ; Vallely MP; McCaughan BC; Jin HC; van Zandwijk N; Reid G
    J Thorac Oncol; 2013 Oct; 8(10):1317-28. PubMed ID: 24457242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
    de Reyniès A; Jaurand MC; Renier A; Couchy G; Hysi I; Elarouci N; Galateau-Sallé F; Copin MC; Hofman P; Cazes A; Andujar P; Imbeaud S; Petel F; Pairon JC; Le Pimpec-Barthes F; Zucman-Rossi J; Jean D
    Clin Cancer Res; 2014 Mar; 20(5):1323-34. PubMed ID: 24443521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistent lung expansion after pleural talc poudrage in non-surgically resected malignant pleural mesothelioma.
    Rena O; Boldorini R; Papalia E; Mezzapelle R; Baietto G; Roncon A; Casadio C
    Ann Thorac Surg; 2015 Apr; 99(4):1177-83. PubMed ID: 25669666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Immunotherapy and malignant mesothelioma: clinical perspectives].
    Grégoire M; Ebstein F
    Bull Cancer; 2007 Jan; 94(1):23-31. PubMed ID: 17237002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.
    Tolani B; Acevedo LA; Hoang NT; He B
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29342862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disparities in Compliance With National Guidelines for the Treatment of Malignant Pleural Mesothelioma.
    Espinoza-Mercado F; Borgella JD; Berz D; Alban RF; Sarkissian A; Imai HTA; Soukiasian HJ
    Ann Thorac Surg; 2019 Sep; 108(3):889-896. PubMed ID: 31004585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications.
    Suraokar MB; Nunez MI; Diao L; Chow CW; Kim D; Behrens C; Lin H; Lee S; Raso G; Moran C; Rice D; Mehran R; Lee JJ; Pass HI; Wang J; Momin AA; James BP; Corvalan A; Coombes K; Tsao A; Wistuba II
    Ann Oncol; 2014 Jun; 25(6):1184-92. PubMed ID: 24669013
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Signal Transducer and Activator of Transcription 1 (STAT1) Knock-down Induces Apoptosis in Malignant Pleural Mesothelioma.
    Arzt L; Halbwedl I; Gogg-Kamerer M; Popper HH
    Pathol Oncol Res; 2017 Jul; 23(3):595-605. PubMed ID: 27987139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.
    Bograd AJ; Suzuki K; Vertes E; Colovos C; Morales EA; Sadelain M; Adusumilli PS
    Cancer Immunol Immunother; 2011 Nov; 60(11):1509-27. PubMed ID: 21913025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: an individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation.
    Hasan B; Greillier L; Pallis A; Menis J; Gaafar R; Sylvester R; Fennell DA; Baas P; Surmont V; Van Meerbeeck JP; O'brien ME
    Eur J Cancer; 2014 Nov; 50(16):2771-82. PubMed ID: 25155251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A review of bevacizumab in the treatment of malignant pleural mesothelioma.
    Brosseau S; Assoun S; Naltet C; Steinmetz C; Gounant V; Zalcman G
    Future Oncol; 2017 Dec; 13(28):2537-2546. PubMed ID: 29086616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pleural mesothelioma: is the surgeon still there?
    Opitz I; Weder W
    Ann Oncol; 2018 Aug; 29(8):1710-1717. PubMed ID: 29905765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What's the place of immunotherapy in malignant mesothelioma treatments?
    Grégoire M
    Cell Adh Migr; 2010; 4(1):153-61. PubMed ID: 20179421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trimodality Treatment of Malignant Pleural Mesothelioma: An Institutional Review.
    Kapeles M; Gensheimer MF; Mart DA; Sottero TL; Kusano AS; Truong A; Farjah F; Laramore GE; Stelzer KJ; Patel SA
    Am J Clin Oncol; 2018 Jan; 41(1):30-35. PubMed ID: 26353120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma.
    Berardi R; Fiordoliva I; De Lisa M; Ballatore Z; Caramanti M; Morgese F; Savini A; Rinaldi S; Torniai M; Tiberi M; Ferrini C; Onofri A; Cascinu S
    Tumori; 2016; 102(2):190-5. PubMed ID: 26893272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-institution experience of intensity-modulated radiotherapy for malignant pleural mesothelioma at University of Catania.
    Spatola C; Militello C; Tocco A; Salamone V; Luigi R; Migliore M; Marletta D; Cannizzaro A; Bevilacqua R; Milone P; Pergolizzi S; Privitera G
    Future Oncol; 2018 Mar; 14(6s):17-21. PubMed ID: 29400553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese study.
    Wu TH; Lee LJ; Yuan CT; Chen TW; Yang JC
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):230-236. PubMed ID: 29709339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.
    You M; Varona-Santos J; Singh S; Robbins DJ; Savaraj N; Nguyen DM
    J Thorac Cardiovasc Surg; 2014 Jan; 147(1):508-16. PubMed ID: 24094913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.